NDAORALSOLUTION
Approved
Mar 2014
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
1
Data completeness
7/8 — Comprehensive
HEMANGEOL (propranolol hydrochloride) by Pierre Fabre is hemangeol's effects on infantile hemangiomas is not well understood. Approved for infantile hemangioma. First approved in 2014.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HEMANGEOL is an oral propranolol hydrochloride solution approved for infantile hemangioma, a common benign vascular tumor in infants. The mechanism of action remains incompletely understood, though propranolol's beta-blocking properties are believed to play a role. The drug is also being studied off-label across multiple oncology and cardiovascular indications.
$13KPart D
LOE ApproachingDeclining
2.4 years to LOENiche orphan product with negligible commercial scale; small, specialized team focused on rare pediatric indication.
Mechanism of Action
HEMANGEOL's effects on infantile hemangiomas is not well understood.
Indications (1)
Clinical Trials (1)
Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer
Started Nov 2024
6 enrolled
Non Small Cell Lung CancerPropranolol
Why This Matters for Your Career
Worked on HEMANGEOL at Pierre Fabre? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.